Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Dec
09
Today In Oncology
One in Three Families of Children With ALL Face Financial Hardship During Treatment
Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes
Non-Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL
Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL
New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo